Ambry Genetics Countersues Myriad Genetics Alleging Antitrust Violations | GenomeWeb

NEW YORK (GenomeWeb News) – In response to Myriad Genetics' patent infringement lawsuit against Ambry Genetics, the Aliso Viejo, Calif.-based testing firm took its own legal action today by countersuing Myriad for antitrust violations.

"Myriad's lawsuit is in violation of the Sherman Antitrust Act because the asserted claims against Ambry are invalid under two [US] Supreme Court decisions and Federal Circuit authority," the company said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.